Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation
Mark A. Currier(Nationwide Children's Hospital), Timothy P. Cripe(Nationwide Children's Hospital)
Cited by 30
Related Papers
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
|Clinical Cancer Research|2017|137
Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
|Molecular Cancer Therapeutics|2008|128